Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutated Non-small Cell Lung Cancer Patients”

457 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 457 results

Not applicableUnknownNCT04909073
What this trial is testing

Observational Study of Afatinib 30 mg Daily

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06752408
What this trial is testing

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking Union Medical College Hospital 316
Early research (Phase 1)UnknownNCT05555212
What this trial is testing

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 72
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Not applicableStudy completedNCT01790217
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Large-scale testing (Phase 3)UnknownNCT02859077
What this trial is testing

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Looking for participantsNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04988295
What this trial is testing

Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 776
Not applicableStudy completedNCT04795245
What this trial is testing

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 805
Large-scale testing (Phase 3)Active Not RecruitingNCT04695925
What this trial is testing

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Who this might be right for
Non-small Cell CarcinomaEGFR Gene Mutation
Li Zhang, MD 294
Not applicableStudy completedNCT03721289
What this trial is testing

Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 463
Not applicableNot Yet RecruitingNCT06117644
What this trial is testing

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 30
Post-approval studies (Phase 4)UnknownNCT02778893
What this trial is testing

Conmana Combined With Thalidomide to Treat NSCLC

Who this might be right for
NSCLC
Henan Provincial People's Hospital 67
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)UnknownNCT04646824
What this trial is testing

Almonertinib With Chemotherapy in mEGFR NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Tianjin Medical University Cancer Institute and Hospital 10
Large-scale testing (Phase 3)UnknownNCT02633189
What this trial is testing

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
National Cancer Institute, Naples 200
Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Not applicableStudy completedNCT02475720
What this trial is testing

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 2,000
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988
What this trial is testing

DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Who this might be right for
Non-small Cell Lung Cancer
Dizal Pharmaceuticals 324
Next Page